Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price19.66 USD
Fair value22.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-16Read Accumulation17.87+10.0% to today ✓Markdown gives way to Accumulation
2026-10-02Read Markdown18.16+8.3% to today Accumulation gives way to Markdown after a 16% slide in 3 weeks
2026-09-12Read Accumulation21.59-8.9% to today Markup gives way to Accumulation after a 15% rise in 10 weeks
2026-07-02Read Markup18.70+5.1% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Shoulder Innovations Inc holds its Accumulation at $19.66. Elevated stress, defensive posture warranted, held for 38 days.
As held on the ledger · 2026-10-23
Phase
Accumulation
Quantitative state
Elevated stress, defensive posture warranted, held for 38 days
Price at the screen
$19.66
Valuation
N/A trailing · -15.48 forward price to earnings
Values screen
FAIL· score 70.0
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
8.84%
Below 33%
Interest-bearing debt is just 8.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
57.35%
Below 33%
Interest-bearing cash and securities are 57.3% of assets, above the one-third limit.
Fail
Receivables
20.68%
Below 49%
Money owed to the company is 20.7% of assets, under the 49% limit.
Pass
Revenue purity
4.12%
Below 5%
Only 4.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Shoulder Innovations's business is fine, but its cash and interest-bearing securities are about 57% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SI's ethical verdict changes
Today SI does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 11.9% margin of safety to the base estimate.
Third-party analyst targets: 3 covering, consensus Strong Buy. The average target sits +12% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it none, with a mean price target of $21. Insiders have been net sellers over the past quarter.
2026-10-02Markdown · changed$18.16-15.9%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 15.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it none, with a mean price target of $21. Insiders have been net sellers over the past quarter. Since the last review it its composite score rose.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it none, with a mean price target of $21.
2026-08-12Markup$21.59+15.5%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it none, with a mean price target of $21.
2026-07-18Markup$18.70+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (4 analysts) rates it none, with a mean price target of $21.
2026-07-03Markup$18.70+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$18.70Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.